Evidence map›Paper›PMID 25500683›Full record

ArticleMolecular medicine reports2015

Ultrasound contrast-enhanced imaging and in vitro antitumor effect of paclitaxel-poly(lactic-co-glycolic acid)-monomethoxypoly (ethylene glycol) nanocapsules with ultrasound-targeted microbubble destruction.

Jing Ma, Ling Xi Xing, Ming Shen, Fan Li, Ming Jie Zhu, Li Fang Jin, Zhaojun Li, Feng Gao, Yijin Su, You Rong Duan and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Molecular medicine reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Jing MaDepartment of Ultrasound, Shanghai First People's Hospital Affiliated to Shanghai Jiao tong University School of Medicine, Shanghai 200080, P.R. China.
Ling Xi XingDepartment of Ultrasound, Shanghai First People's Hospital Affiliated to Shanghai Jiao tong University School of Medicine, Shanghai 200080, P.R. China.
Ming ShenCancer Institute, Renji Hospital Affiliated to Shanghai Jiao tong University School of Medicine, Shanghai 200032, P.R. China.
Fan LiDepartment of Ultrasound, Shanghai First People's Hospital Affiliated to Shanghai Jiao tong University School of Medicine, Shanghai 200080, P.R. China.
Ming Jie ZhuCancer Institute, Renji Hospital Affiliated to Shanghai Jiao tong University School of Medicine, Shanghai 200032, P.R. China.
Li Fang JinDepartment of Ultrasound, Shanghai First People's Hospital Affiliated to Shanghai Jiao tong University School of Medicine, Shanghai 200080, P.R. China.
Zhaojun LiDepartment of Ultrasound, Shanghai First People's Hospital Affiliated to Shanghai Jiao tong University School of Medicine, Shanghai 200080, P.R. China.
Feng GaoDepartment of Ultrasound, Shanghai First People's Hospital Affiliated to Shanghai Jiao tong University School of Medicine, Shanghai 200080, P.R. China.
Yijin SuDepartment of Ultrasound, Shanghai First People's Hospital Affiliated to Shanghai Jiao tong University School of Medicine, Shanghai 200080, P.R. China.
You Rong DuanCancer Institute, Renji Hospital Affiliated to Shanghai Jiao tong University School of Medicine, Shanghai 200032, P.R. China.
Lian Fang DuDepartment of Ultrasound, Shanghai First People's Hospital Affiliated to Shanghai Jiao tong University School of Medicine, Shanghai 200080, P.R. China.
Shanghai First People's Hospital · CNRenji Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A combination of diagnostic and therapeutic ultrasound (US) techniques may be able to provide the basis of specific therapeutic protocols, particularly for the treatment of tumors. Nanotechnology may aid the progression towards the use of US for tumor diagnosis and targeted therapy. The current study investigated in vivo and in vitro US contrast imaging using nanocapsules (NCs), and also US and US‑targeted microbubble destruction (UTMD) therapy using drug‑loaded NCs for pancreatic cancer in vitro. In the current study, the NCs were made from the polymer nanomaterial poly(lactic‑co‑glycolic acid)‑monomethoxypoly(ethylene glycol) (PLGA‑mPEG), encapsulated with paclitaxel (PTX), to create PTX‑PLGA‑mPEG NCs. The PTX‑PLGA‑mPEG NCs were used as a US contrast agent (UCA), which produced satisfactory US contrast‑enhanced images in vitro and in vivo of the rabbit kidneys, with good contrast compared with lesions in the peripheral regions. However, clear contrast‑enhanced images were not obtained using PTX‑PLGA‑mPEG NCs as a UCA, when imaging the superficial pancreatic tumors of nude mice in vivo. Subsequently, fluorescence and flow cytometry were used to measure the NC uptake rate of pancreatic tumor cells under various US or UTMD conditions. An MTT assay was used to evaluate the efficiency of PTX and PTX‑PLGA‑mPEG NCs in killing tumor cells following 24 or 48 h of US or UTMD therapy, compared with controls. The specific US or UTMD conditions had been previously demonstrated to be optimal through repeated testing, to determine the conditions by which cells were not impaired and the efficiency of uptake of nanoparticles was highest. The current study demonstrated high cellular uptake rates of PLGA‑mPEG NCs and high tumor cell mortality with PTX‑PLGA‑mPEG NCs under US or UTMD optimal conditions. It was concluded that the use of NCs in US‑mediated imaging and antitumor therapy may provide a novel application for US.

Indexed as

Contrast MediaLactic AcidMicrobubblesNanocapsulesPolyglycolic AcidAnimalsAntineoplastic Agents, PhytogenicCell Line, TumorDrug CarriersDrug Delivery SystemsFlow CytometryHumansMiceMicroscopy, FluorescenceNeoplasmsPaclitaxelAntineoplastic Agents, PhytogenicContrast MediaDrug CarriersLactic AcidNanocapsulesPaclitaxelPolyglycolic AcidPolylactic Acid-Polyglycolic Acid Copolymer

Identifiers

PMID25500683
PMCPMC4337512
OpenAlexW2020684177

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.